|
10082
|
FluMist Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
AstraZeneca plc
|
2003
|
Canada
|
2 - 49 years
|
Single dose
|
Intranasal
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
Tamiflu, Relenza
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10153
|
AdCOVID
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 1
|
Altimmune Inc.
|
NA
|
USA
|
18 - 55 years
|
NA
|
Intranasal
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
33937326
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/
|
NA
|
|
10160
|
CVXGA1
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
CyanVac LLC
|
2021
|
USA
|
18 - 75 years
|
Single dose
|
Intranasal
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA
|
NA
|
NA
|
PIV5-SARS CoV-2 vaccine
|
NA
|
NCT04954287
|
https://clinicaltrials.gov/ct2/show/NCT04954287
|
NA
|
|
10162
|
COVI-VAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Codagenix Inc.
|
2021
|
UK
|
18 - 30 years
|
2 doses 28 days apart
|
Intranasal
|
NA
|
SARS CoV 2 whole virus
|
NA
|
NA
|
Serum Institute of India
|
NA
|
CDX-005
|
33816047
|
NCT04619628
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10175
|
MV-014-212
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Meissa Vaccines Inc.
|
2021
|
USA
|
18 - 69 years
|
2 doses 35 days apart
|
Intranasal
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04798001
|
https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2
|
NA
|
|
10180
|
iNCOVACC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 1
|
Bharat Biotech International Limited
|
2021
|
India
|
18 - 60 years
|
2 doses 28 days apart
|
Intranasal
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
BBV154
|
NA
|
NA
|
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51327
|
NA
|
|
10204
|
HPIV3-EBO-Z ( HPIV3-EbovZ GP Vaccine)
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
|
2015
|
USA
|
18 - 50 years
|
NA
|
Intranasal
|
NA
|
Zaire Ebola virus glycoprotein
|
Live-attenuated human Parainfluenza virus type 3 vectored vaccine expressing Ebolavirus Zaire glycoprotein
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT02564575
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10216
|
Ad-CHIKV-SG
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intranasal
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
Ad-CHIKV-E3/E2/6K, Ad-CHIKV-E3/E2/E1
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10235
|
VXA G1.1 NN
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Vaxart
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
NA
|
HuNoV GII.4
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.mdpi.com/2076-393X/9/7/732/htm
|
NA
|
|
10236
|
Monovalent GI.1 VLPs
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Baylor College of Medicine, University of Maryland School of Medicine
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
MPL
|
HuNoV GI.1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.mdpi.com/2076-393X/9/7/732/htm
|
NA
|
|
10237
|
Transgenic plant-based norovirus vaccine
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Arizona State University
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
Gardiquimod, None when delivered with GelVac
|
Norwalk virus (GI.1) VLP
|
Tobacco mosaic virus derived transient expression system using leaves of Nicotiana benthamiana
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf
|
NA
|
|
10250
|
COVID-19 Vaccine Nasal Spray
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 2
|
Xiamen University
|
2021
|
China
|
18 years and above
|
2 doses 14 days apart
|
Intranasal
|
NA
|
NA
|
NA
|
NA
|
University of Hong Kong, Beijing Wantai Biological Pharmacy
|
NA
|
NA
|
33937326
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/
|
NA
|
|
10264
|
DelNS1-2019-nCoV-RBD-OPT1
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Replicating viral vector
|
Phase 2
|
Beijing Wantai Biological
|
NA
|
NA
|
NA
|
Single dose
|
Intranasal
|
NA
|
NA
|
NA
|
NA
|
Jiangsu Province Centers for Disease Control and Prevention
|
NA
|
NA
|
33816047
|
NCT04809389
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://clinicaltrials.gov/ct2/show/NCT04809389
|
|
10280
|
AV-COVID-19
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 2
|
Aivita Biomedical Inc.
|
2020
|
USA
|
18 years and above
|
NA
|
Intranasal
|
GM-CSF
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT05007496
|
https://clinicaltrials.gov/show/NCT04386252
|
https://clinicaltrials.gov/ct2/show/NCT05007496
|
|
10383
|
NanoVax
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Subunit vaccine
|
Preclinical
|
BlueWillow Biologics
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|
|
10419
|
GII.4 P particles
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Preclinical
|
Cincinnati Children’s Hospital Medical Center
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
NA
|
P particles derived from HuNoV VP1
|
NA
|
NA
|
Southern Medical University, Virginia Polytechnic Institute and State University
|
NA
|
NA
|
NA
|
NA
|
https://www.mdpi.com/2076-393X/9/7/732/htm
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851174/
|
|
10420
|
Plant-expressed GII.4 VLPs
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Preclinical
|
Arizona State University
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
NA
|
HuNoV GII.4 VLP
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.mdpi.com/2076-393X/9/7/732/htm
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054422/
|
|
10422
|
Norovirus P particle and combination vaccines
|
Norovirus Infection
|
Gastrointestinal
|
Norovirus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Preclinical
|
Cincinnati Children’s Hospital Medical Center
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
Chitosan, MPL and TNC buffer
|
P domains representing different GI and GII strains
|
Baculovirus vector in E.coli or yeast system
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf
|
NA
|